272 related articles for article (PubMed ID: 29483097)
1. Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.
He L; Tang J; Andersson EI; Timonen S; Koschmieder S; Wennerberg K; Mustjoki S; Aittokallio T
Cancer Res; 2018 May; 78(9):2407-2418. PubMed ID: 29483097
[TBL] [Abstract][Full Text] [Related]
2. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Boidol B; Kornauth C; van der Kouwe E; Prutsch N; Kazianka L; Gültekin S; Hoermann G; Mayerhoefer ME; Hopfinger G; Hauswirth A; Panny M; Aretin MB; Hilgarth B; Sperr WR; Valent P; Simonitsch-Klupp I; Moriggl R; Merkel O; Kenner L; Jäger U; Kubicek S; Staber PB
Blood; 2017 Dec; 130(23):2499-2503. PubMed ID: 28972014
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Andersson EI; Pützer S; Yadav B; Dufva O; Khan S; He L; Sellner L; Schrader A; Crispatzu G; Oleś M; Zhang H; Adnan-Awad S; Lagström S; Bellanger D; Mpindi JP; Eldfors S; Pemovska T; Pietarinen P; Lauhio A; Tomska K; Cuesta-Mateos C; Faber E; Koschmieder S; Brümmendorf TH; Kytölä S; Savolainen ER; Siitonen T; Ellonen P; Kallioniemi O; Wennerberg K; Ding W; Stern MH; Huber W; Anders S; Tang J; Aittokallio T; Zenz T; Herling M; Mustjoki S
Leukemia; 2018 Mar; 32(3):774-787. PubMed ID: 28804127
[TBL] [Abstract][Full Text] [Related]
4. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Herbaux C; Kornauth C; Poulain S; Chong SJF; Collins MC; Valentin R; Hackett L; Tournilhac O; Lemonnier F; Dupuis J; Daniel A; Tomowiak C; Laribi K; Renaud L; Roos-Weil D; Rossi C; Van Den Neste E; Leyronnas C; Merabet F; Malfuson JV; Tiab M; Ysebaert L; Ng S; Morschhauser F; Staber PB; Davids MS
Blood; 2021 Jun; 137(25):3495-3506. PubMed ID: 33598678
[TBL] [Abstract][Full Text] [Related]
5. Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma.
Berlow NE; Rikhi R; Geltzeiler M; Abraham J; Svalina MN; Davis LE; Wise E; Mancini M; Noujaim J; Mansoor A; Quist MJ; Matlock KL; Goros MW; Hernandez BS; Doung YC; Thway K; Tsukahara T; Nishio J; Huang ET; Airhart S; Bult CJ; Gandour-Edwards R; Maki RG; Jones RL; Michalek JE; Milovancev M; Ghosh S; Pal R; Keller C
BMC Cancer; 2019 Jun; 19(1):593. PubMed ID: 31208434
[TBL] [Abstract][Full Text] [Related]
6. Network Propagation Predicts Drug Synergy in Cancers.
Li H; Li T; Quang D; Guan Y
Cancer Res; 2018 Sep; 78(18):5446-5457. PubMed ID: 30054332
[TBL] [Abstract][Full Text] [Related]
7. Integrated Analysis of Drug Sensitivity and Selectivity to Predict Synergistic Drug Combinations and Target Coaddictions in Cancer.
Jaiswal A; Yadav B; Wennerberg K; Aittokallio T
Methods Mol Biol; 2019; 1888():205-217. PubMed ID: 30519949
[TBL] [Abstract][Full Text] [Related]
8. SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy.
Ianevski A; Timonen S; Kononov A; Aittokallio T; Giri AK
PLoS Comput Biol; 2020 Feb; 16(2):e1007604. PubMed ID: 32012154
[TBL] [Abstract][Full Text] [Related]
9. Stratification and prediction of drug synergy based on target functional similarity.
Yang M; Jaaks P; Dry J; Garnett M; Menden MP; Saez-Rodriguez J
NPJ Syst Biol Appl; 2020 Jun; 6(1):16. PubMed ID: 32487991
[TBL] [Abstract][Full Text] [Related]
10. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer.
Malyutina A; Majumder MM; Wang W; Pessia A; Heckman CA; Tang J
PLoS Comput Biol; 2019 May; 15(5):e1006752. PubMed ID: 31107860
[TBL] [Abstract][Full Text] [Related]
11. In silico drug combination discovery for personalized cancer therapy.
Jeon M; Kim S; Park S; Lee H; Kang J
BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
[TBL] [Abstract][Full Text] [Related]
12. Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia.
Mikhaylenko N; Wahnschaffe L; Herling M; Roeder I; Seifert M
PLoS One; 2022; 17(9):e0274463. PubMed ID: 36129940
[TBL] [Abstract][Full Text] [Related]
13. Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways.
Braun T; Glass M; Wahnschaffe L; Otte M; Mayer P; Franitza M; Altmüller J; Hallek M; Hüttelmaier S; Schrader A; Herling M
Haematologica; 2022 Jan; 107(1):187-200. PubMed ID: 33543866
[TBL] [Abstract][Full Text] [Related]
14. Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer.
Jaeger S; Igea A; Arroyo R; Alcalde V; Canovas B; Orozco M; Nebreda AR; Aloy P
Cancer Res; 2017 Jan; 77(2):459-469. PubMed ID: 27879272
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL).
Ozpuyan F; Meyer P; Ni H; Al-Masri H; Alkan S
Leuk Lymphoma; 2007 Nov; 48(11):2247-50. PubMed ID: 17990182
[No Abstract] [Full Text] [Related]
16. Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia.
Brothers J; Castillo DR; Jeon WJ; Joung B; Linhares Y
Hematology; 2023 Dec; 28(1):2237342. PubMed ID: 37485976
[No Abstract] [Full Text] [Related]
17. Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms.
Axelrod M; Gordon VL; Conaway M; Tarcsafalvi A; Neitzke DJ; Gioeli D; Weber MJ
Oncotarget; 2013 Apr; 4(4):622-35. PubMed ID: 23599172
[TBL] [Abstract][Full Text] [Related]
18. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
[TBL] [Abstract][Full Text] [Related]
19. Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death.
Guest ST; Kratche ZR; Irish JC; Wilson RC; Haddad R; Gray JW; Garrett-Mayer E; Ethier SP
Oncotarget; 2016 Jun; 7(24):36138-36153. PubMed ID: 27153554
[TBL] [Abstract][Full Text] [Related]
20. Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells.
Athanasiadis P; Ianevski A; Skånland SS; Aittokallio T
Methods Mol Biol; 2022; 2449():327-348. PubMed ID: 35507270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
